Ontology type: schema:ScholarlyArticle
2005-11-04
AUTHORSAndrea Kuendgen, Sabine Knipp, Frank Fox, Corinna Strupp, Barbara Hildebrandt, Christian Steidl, Ulrich Germing, Rainer Haas, Norbert Gattermann
ABSTRACTValproic acid (VPA) inhibits histone deacetylase activity and induces differentiation of acute myeloid leukemia (AML) blasts in vitro. We observed clinical responses to VPA in patients with myelodysplastic syndrome (MDS) and AML. Here, we report follow-up data on 75 patients. Of these, 66 were started on VPA monotherapy, with later addition of all-trans retinoic acid (ATRA) in patients who did not respond or relapsed. Nine patients were treated with VPA + ATRA from the start. Median treatment duration was 4 months for VPA and 2 months for ATRA. Hematological improvement, according to international working group criteria for MDS, was observed in 18 patients (24%). Median response duration was 4 months. ATRA exerted no additional effect in patients receiving the combination from the start or benefited primary VPA nonresponders. However, of ten VPA responders who relapsed, four achieved a second response after addition of ATRA. Response rates were strongly dependent on disease type according to WHO classification. We found a response rate of 52% in MDS patients with a normal blast count (refractory sideroblastic anemia, refractory cytopenia with multilineage dysplasia, and refractory sideroblastic cytopenia with multilineage dysplasia). The response rate was 6% in refractory anemia with excess blasts (I + II), 16% in AML, and 0% in chronic myelomonocytic leukemia. Bone marrow blast count was the only variable that predicted responses. We conclude that VPA is clinically useful in low-risk MDS. For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs. If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response. More... »
PAGES61-66
http://scigraph.springernature.com/pub.10.1007/s00277-005-0026-8
DOIhttp://dx.doi.org/10.1007/s00277-005-0026-8
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1016568654
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16270213
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Acute Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cell Differentiation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Histone Deacetylase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Histone Deacetylases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kaplan-Meier Estimate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myelodysplastic Syndromes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tretinoin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Valproic Acid",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Kuendgen",
"givenName": "Andrea",
"id": "sg:person.01022105364.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Knipp",
"givenName": "Sabine",
"id": "sg:person.0660430701.17",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660430701.17"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Fox",
"givenName": "Frank",
"id": "sg:person.01130535257.35",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130535257.35"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Strupp",
"givenName": "Corinna",
"id": "sg:person.01001653715.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Hildebrandt",
"givenName": "Barbara",
"id": "sg:person.01320675564.15",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology, University of G\u00f6ttingen, G\u00f6ttingen, Germany",
"id": "http://www.grid.ac/institutes/grid.7450.6",
"name": [
"Department of Hematology/Oncology, University of G\u00f6ttingen, G\u00f6ttingen, Germany"
],
"type": "Organization"
},
"familyName": "Steidl",
"givenName": "Christian",
"id": "sg:person.01111177670.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111177670.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Germing",
"givenName": "Ulrich",
"id": "sg:person.01362464041.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Haas",
"givenName": "Rainer",
"id": "sg:person.01127414674.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/561",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027172656",
"https://doi.org/10.1038/561"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/5047",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020518662",
"https://doi.org/10.1038/5047"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1476-4598-4-22",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015355581",
"https://doi.org/10.1186/1476-4598-4-22"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00023210-200216100-00003",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046120351",
"https://doi.org/10.2165/00023210-200216100-00003"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.leu.2403528",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017032889",
"https://doi.org/10.1038/sj.leu.2403528"
],
"type": "CreativeWork"
}
],
"datePublished": "2005-11-04",
"datePublishedReg": "2005-11-04",
"description": "Valproic acid (VPA) inhibits histone deacetylase activity and induces differentiation of acute myeloid leukemia (AML) blasts in vitro. We observed clinical responses to VPA in patients with myelodysplastic syndrome (MDS) and AML. Here, we report follow-up data on 75 patients. Of these, 66 were started on VPA monotherapy, with later addition of all-trans retinoic acid (ATRA) in patients who did not respond or relapsed. Nine patients were treated with VPA + ATRA from the start. Median treatment duration was 4 months for VPA and 2 months for ATRA. Hematological improvement, according to international working group criteria for MDS, was observed in 18 patients (24%). Median response duration was 4 months. ATRA exerted no additional effect in patients receiving the combination from the start or benefited primary VPA nonresponders. However, of ten VPA responders who relapsed, four achieved a second response after addition of ATRA. Response rates were strongly dependent on disease type according to WHO classification. We found a response rate of 52% in MDS patients with a normal blast count (refractory sideroblastic anemia, refractory cytopenia with multilineage dysplasia, and refractory sideroblastic cytopenia with multilineage dysplasia). The response rate was 6% in refractory anemia with excess blasts (I + II), 16% in AML, and 0% in chronic myelomonocytic leukemia. Bone marrow blast count was the only variable that predicted responses. We conclude that VPA is clinically useful in low-risk MDS. For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs. If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response.",
"genre": "article",
"id": "sg:pub.10.1007/s00277-005-0026-8",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1358129",
"issn": [
"0939-5555",
"1432-0584"
],
"name": "Annals of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "Suppl 1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "84"
}
],
"keywords": [
"acute myeloid leukemia",
"myelodysplastic syndrome",
"trans retinoic acid",
"response rate",
"blast count",
"myeloid leukemia",
"inhibits histone deacetylase activity",
"refractory acute myeloid leukemia",
"lower-risk myelodysplastic syndromes",
"bone marrow blast count",
"high-risk myelodysplastic syndrome",
"International Working Group criteria",
"median treatment duration",
"median response duration",
"marrow blast count",
"phase 2 study",
"retinoic acid",
"chronic myelomonocytic leukemia",
"addition of ATRA",
"second response",
"VPA monotherapy",
"clinical response",
"hematological improvement",
"excess blasts",
"MDS patients",
"refractory anemia",
"Group criteria",
"WHO classification",
"myelomonocytic leukemia",
"histone deacetylase activity",
"response duration",
"valproic acid",
"patients",
"treatment duration",
"VPA responders",
"disease type",
"VPA",
"leukemia",
"only variable",
"initial response",
"ATRA",
"months",
"deacetylase activity",
"syndrome",
"additional effect",
"duration",
"count",
"response",
"monotherapy",
"nonresponders",
"chemotherapy",
"anemia",
"follow",
"responders",
"drugs",
"rate",
"start",
"acid",
"latest addition",
"blasts",
"differentiation",
"combination",
"addition",
"criteria",
"activity",
"study",
"effect",
"improvement",
"data",
"variables",
"classification",
"types",
"potential",
"results"
],
"name": "Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia",
"pagination": "61-66",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1016568654"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00277-005-0026-8"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16270213"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00277-005-0026-8",
"https://app.dimensions.ai/details/publication/pub.1016568654"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:55",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_395.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00277-005-0026-8"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0026-8'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0026-8'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0026-8'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0026-8'
This table displays all metadata directly associated to this object as RDF triples.
296 TRIPLES
21 PREDICATES
124 URIs
110 LITERALS
26 BLANK NODES